Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Tue, 14th Aug 2012 12:35

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we make our plans for a subsequent Phase II clinical trial application with ReNeuron's ReN001 cell-based treatment for stroke disability,' said ReNeuron's Chief Executive Michael Hunt.The therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke. The group also announced that one patient in the trial has now been successfully treated with ReN001 and discharge from hospital with no acute safety issues arising. Shares jumped 14.91% to 3.7p.Speech recognition and payment solutions group Eckoh has secured a two-year contract with UK baby website Kiddicare to provide secure card payment services over the phone. "This is the second EckohPROTECT contract to be secured in quick succession through the new referral agreement with a global service provider that was announced in May 2012," the firm said. Shares were up 7.84% at 13.75p.Healthcare Locums, the nursing, media and social services recruitment group, saw shares rocket 23.29% to 2.25p today after announcing that it would not bother filing a defence against legal claims in the US as it has no interests in the country and therefore does not abide by US law. The complaint accuses the company and some of its former directors of making "misrepresentations" during 2012 concerning its profitability and accounting practices, something that the firm disagrees with.The group told the plaintiffs' US counsel that the underlying claim is "wholly without merit and that if proceedings are commenced in the proper forum they will be strenuously defended."BC
More News
2 Dec 2022 10:40

AIM WINNERS & LOSERS: Orosur Mining drops on disappointing assays

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
2 Dec 2022 09:31

ReNeuron loss narrows amid lower costs and surging revenue

(Alliance News) - ReNeuron Group PLC on Friday said its loss narrowed in the first half of its financial year, following lower costs, increased revenue and foreign exchange gains.

Read more
7 Oct 2022 10:32

ReNeuron says exosomes outperform alternatives at Boston summit

(Alliance News) - ReNeuron Group PLC on Friday said it presented positive new data at a leading summit of targeted therapies.

Read more
14 Sep 2022 13:19

IN BRIEF: ReNeuron promotes Financial Controller Hawkins to CFO

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Promotes Financial Controller John Hawkins to chief financial officer with immediate effect. Hawkins joined the company in 2014 as financial controller and was also named as the company secretary last year. Says Hawkins is an experienced finance professional with a breadth of experience gained within "a variety of businesses, from large PLCs to family-owned SMEs".

Read more
2 Sep 2022 15:57

UK shareholder meetings calendar - next 7 days

Monday 5 September 
Highway Capital PLCAGM
Hill & Smith Holdings PLCAGM
Hydrogen Utopia International PLCAGM
LXi REIT PLCAGM
Monks Investment Trust PLCAGM
Totally PLCAGM
Tuesday 6 September 
Ashtead Group PLCAGM
Berkeley Group Holdings PLCAGM
Brickability Group PLCAGM
Castelnau Group LtdAGM
DS Smith PLCAGM
Lamprell PLCAGM
Renold PLCAGM
Wednesday 7 September 
BlueRock Diamonds PLCAGM
CVC Income & Growth LtdEGM
Halfords Group PLCAGM
Jupiter Green Investment Trust PLCAGM
Mulberry Group PLCAGM
Okyo Pharma LtdAGM
Polar Capital Holdings PLCAGM
Redcentric PLCAGM
Seed Innovations LtdAGM
Trifast PLCAGM
Yellow Cake PLCAGM
Thursday 8 September 
Atlantis Japan Growth Fund LtdAGM
Aston Martin Lagonda Global Holdings PLCGM proposed equity capital raise
Caretech Holdings PLCGM takeover by Sheikh Holdings Group
Chariot LtdAGM
Chelverton UK Dividend Trust PLCAGM
Currys PLCAGM
Euromoney Institutional Investor PLCGM re takeover offer by Astorg and Epiris
Gabelli Merger Plus+ Trust PLCGM tender offers
Invesco Asia Trust PLCAGM
LendInvest PLCAGM
Lindsell Train Investment Trust PLCAGM
Montanaro European Smaller Cos Trust PLCAGM
ScotGems PLCGM re voluntary liquidation
Semper Fortis Esports PLCAGM
Severfield PLCAGM
Speedy Hire PLCAGM
SysGroup PLCAGM
WH Ireland Group PLCAGM
XPS Pensions Group PLCAGM
Friday 9 September 
Baillie Gifford UK Growth Trust PLC
AGM
CLS Holdings PLCGM re tender offer
Gear4Music Holdings PLCAGM
Newcrest Mining LtdAGM
Pensana PLCAGM
ReNeuron Group PLCAGM
SVM UK Emerging Fund PLCAGM
Victoria Oil & Gas PLCAGM
Voyager Life PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
1 Aug 2022 14:30

EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

Read more
4 Jul 2022 10:22

IN BRIEF: ReNeuron annual loss narrows amid shift in strategy

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Pretax loss in year to March 31 narrows to GBP11.1 million from GBP13.4 million loss a year prior. Research & development costs fall to GBP8.1 million from GBP9.5 million, with general & administrative costs at GBP3.6 million versus GBP3.7 million. Revenue drops to GBP403,000 from GBP257,000.

Read more
1 Jul 2022 13:40

IN BRIEF: ReNeuron inks deal worth up to GBP6 million in revenue

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Negotiates a supplemental terms agreement with Shanghai Fosun Pharmaceutical Group Co Ltd. Company says the agreement has the potential to generate revenue of up to GBP6 million.

Read more
27 Jun 2022 15:53

UK earnings, trading statements calendar - next 7 days

Tuesday 28 June 
Appreciate Group PLCFull Year Results
ICG Enterprise Trust PLCQ1 Results
IG Design Group PLCFull Year Results
Marlowe PLCFull Year Results
Oxford BioDynamics PLCHalf Year Results
Petrofac LtdTrading Statement
Wise PLCFull Year Results
Wednesday 29 June 
B&M European Value Retail SAQ1 Results
LendInvest PLCFull Year Results
Moonpig Group PLCFull Year Results
Inspecs Group PLCFull Year Results
Mulberry Group PLCFull Year Results
ProCook Group PLCFull Year Results
Thursday 30 June 
Accsys Technologies PLCFull Year Results
Breedon Group PLCHalf Year Results
Bunzl PLCTrading Statement
Civitas Social Housing PLCFull Year Results
HgCapital Trust PLCHalf Year Results
Hunting PLCTrading Statement
Polar Capital Holdings PLCFull Year Results
PCF Group PLCFull Year Results
Renalytix PLCQ3 Results
SDCL Energy Efficiency Income Trust PLCFull Year Results
SEEEN PLCFull Year Results
Friday 1 July 
no events scheduled 
Monday 4 July 
Augmentum Fintech PLCFull Year Results
Porvair PLCHalf Year Results
ReNeuron Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
11 Feb 2022 13:50

IN BRIEF: ReNeuron chair steps in to run business as CEO resigns

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology - Olav Hellobo resigns as chief executive officer after seven years and will leave at the end of February. Hellobo says he decided it was time to leave following ReNeuron's recent change in strategy. The company has shifted its focus to the development of its exosomes technology platform. The platform uses stem cell technologies to develop "off the shelf" treatments for diseases. Chair Iain Ross, supported by Chief Financial Officer Catherine Isted, will run the business, ReNeuron says.

Read more
18 Jan 2022 10:58

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

Read more
18 Jan 2022 10:26

ReNeuron shares dive as it drops retinitis pigmentosa trials

ReNeuron shares dive as it drops retinitis pigmentosa trials

Read more
13 Jan 2022 21:12

TRADING UPDATES: Power Metal renewal; Yamana production hits target

TRADING UPDATES: Power Metal renewal; Yamana production hits target

Read more
11 Jan 2022 16:00

ReNeuron re-appoints Randolph Corteling in senior research role

ReNeuron re-appoints Randolph Corteling in senior research role

Read more
30 Nov 2021 19:13

TRADING UPDATES: Zambeef sales continue climb; Watchstone files claim

TRADING UPDATES: Zambeef sales continue climb; Watchstone files claim

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.